| HOME >> BIOLOGY >> TECHNOLOGY |
Existing investor, Nick Wright, Fund Manager of the East Midlands Early Growth Fund at E-Synergy was naturally pleased with the company's continued success: "For us, Critical Pharmaceuticals is an ideal showcase for the region's excellence in pharmaceutical services. By combining worldclass research with knowledge of the real needs of the pharmaceutical sector, Critical Pharmaceuticals has made rapid progress. We now welcome the involvement of new investors to help take the company through the next exciting stage of its development."
About Critical Pharmaceuticals
Critical Pharmaceuticals is a Nottingham UK-based biotechnology company
with proprietary drug delivery technologies for the sustained release and
nasal delivery of proteins and peptides and labile or insoluble small
molecules. Critical Pharmaceuticals was founded by Professor Steve Howdle
in 2002 based on his world leading research into supercritical fluids.
Professor Howdle noticed that supercritical carbon dioxide was able to
liquify certain polymers, and in a moment of inspiration realised that this
could be used to encapsulate thermally labile or solvent sensitive drugs to
create injectable sustained release products. As well as working in
partnership with other pharmaceutical and biotechnology companies, the
company is now developing a pipeline of reformulated drug candidates for
areas of unmet needs including human growth hormone. For more information
visit http://www.criticalpharmaceuticals.com
Corporate Inquiries
Lisbeth Illum, Chief Executive Officer
Critical Pharmaceuticals
BioCity Nottingham, NG1 1GF, UK
Tel +44-115-
'/>"/>
| SOURCE Critical Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved |